Aquinox Pharmaceuticals (canada) Inc.

Aquinox Pharmaceuticals Inc.

Naeja-rgm Pharmaceuticals Inc.

Naeja-rgm Pharmaceuticals Ulc

Rudong Shan

Curtis Harwig

Jeremy D Pettigrew

Vladimir Khlebnikov

David Earl Bogucki

Jeffery R Raymond

Lloyd F Mackenzie

Thomas B MacRury

Samarendra N Maiti

Rong Ling

Judy Yip

Dai Quoc Nguyen

Andhe V N Reddy

Chan Minh Ha

Madhava Reddy Madala

Lloyd Mackenzie

Paul Bird

Tom MacRury

Noor Aini Bhatti

Sam Place

Samarendra Nath Maiti

Andhe Vn Reddy

Cephem compounds, pharmaceutically acceptable salts thereof, and methods of using same, wherein the compound has a bicyclic nitrogen-containing aromatic heterocyclic ring as the quaternary ammoniomethyl group at the 3-position and one or both of a terminal amidine residue (substituted or unsubstituted) attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain, or a terminal guanidine residue attached to an aryl or a 5- or 6-membered heteroaryl group (substituted or unsubstituted) which is further attached through a spacer to the free N-atom of the quaternary nitrogen-containing bicyclic ring at the 3-side chain.

Cephem compounds, their production and use

Compounds of formula (I): where n, R, R, R, R, Rand Rare defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

SHIP1 modulators and methods related thereto

Compounds of formula (I): where, n, R, R, R, R, Rand Rare defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 

Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R, R, R, R, R, Rand Rare as defined herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Growing community of inventors

Edmonton, Canada

Rudong Shan